OxygenRich Intelligent Medical Completes Seed Round Financing with Riemann Hypothesis as Exclusive Financial Advisor
Riemann-Hypothesis
Boutique Investment Bank in the Biomedical Field
As our exclusive financial advisor for this fundraising round, we are delighted to have established a deep and long-term partnership with the Riemann-Hypothesis team. From our initial contact, we were impressed by their professionalism and dedication. Their “fully managed service model” resonated strongly with us as entrepreneurs, allowing us to focus wholeheartedly on business development with ease and efficiency, while avoiding the costs of trial and error. Throughout the fundraising process, the Riemann-Hypothesis team’s professionalism, diligence, and sense of responsibility left a profound impression on us, providing comprehensive support for our company’s capital raising. We sincerely appreciate the team’s efforts and look forward to further deepening our collaboration and achieving even greater success together!
— Huang Yong, Co-founder of Oxygen Rich Medical
Recently, Nanjing Oxygen Rich Intelligent Medical Technology Co., Ltd. (hereinafter referred to as “Oxygen Rich Medical” or the “Company”)—Internationally LeadingIntelligent Diagnosis and Treatment Platform for Pulmonary Vascular Diseases Announces Completion of Its First Seed Funding Round, Led by Nanjing Juyi TechnologyRiemann-Hypothesis Serves as the Exclusive Financial Advisor for This Round of Financing. The funding from this round will be used to support the product development and team building of the pulmonary artery image processing system.
Oxygen Rich Medical was established in June 2022, jointly founded by a multidisciplinary team from Beijing Chaoyang Hospital and an artificial intelligence team from Southeast University. With over 15 years of deep expertise in the diagnosis and treatment of pulmonary embolism, the company’s core team has developed an internationally leading AI-based clinical decision support system for diagnosing pulmonary embolism. Built upon the world’s first diagnostic-grade intelligent map of pulmonary vasculature, this system addresses the industry-wide challenges of high misdiagnosis and missed diagnosis rates. It comprehensively meets the screening needs for pulmonary embolism and other lung diseases, positioning Oxygen Rich Medical as a pioneer in the intelligent diagnosis of both acute and chronic pulmonary embolism.
The company’s core founding team includes the Pulmonary Embolism Team from Beijing Chaoyang Hospital, which boasts a profound academic heritage and exceptional clinical expertise, standing as a top-tier domestic expert group in the diagnosis and treatment of pulmonary embolism; the Artificial Intelligence Team from Southeast University, which possesses robust technical resources and extensive experience in product research and development; and an engineering operations team with a successful track record in medical device startups, accelerating industrialization through the integration of medicine and engineering. Furthermore, the collaboration among top-tier tertiary hospitals, renowned universities, and industry commercialization experts will provide Oxygen Rich Medical with a continuous stream of innovation-driven momentum.
Huang Yong, Co-founder of Oxygen Rich Medicalstated, “We extend our sincere gratitude to the company’s robust and professional founding team for their continued efforts, and to our investors for their steadfast support and trust. The successful completion of this financing round serves as a full endorsement of Oxygen Rich Medical’s operational capabilities and the development potential of its technology platform. Leveraging China’s leading clinical experience and scientific research achievements, and employing advanced artificial intelligence technologies, the company will establish an internationally innovative diagnostic development platform and product pipeline for pulmonary embolism. This initiative aims to provide user-friendly and widely accessible intelligent solutions for pulmonary embolism to patients with pulmonary vascular diseases and high-risk populations.”
Nanjing Juyi Technologystated: “We are delighted to participate in the seed round investment of Oxygen Rich Medical. Pulmonary embolism is characterized by acute onset, high mortality, a large patient population, and complex pathology. There is a high rate of misdiagnosis and missed diagnosis in clinical practice, and existing screening and diagnostic methods have significant limitations. The AI-assisted diagnostic decision support system for pulmonary embolism, independently developed by Oxygen Rich Medical, provides auxiliary diagnosis for both acute and chronic pulmonary embolism. It offers a complete solution that is intelligent, one-stop, end-to-end, and standardized for clinical diagnosis. This system addresses the challenges of high missed diagnosis rates, high treatment costs, technical complexity, and suboptimal outcomes associated with pulmonary embolism, thereby bringing benefits to patients, reducing physicians’ workload, and saving medical resources. Led by respiratory physicians, the project integrates medicine and engineering. The team possesses extensive entrepreneurial experience and industry resources, along with profound technological expertise. These factors underpin our strong confidence in the sustained and rapid future growth of Oxygen Rich Medical.”
Dr. Li Chaoxing, Chairman of Riemann-Hypothesis, as the exclusive financial advisor for this round of financingIt stated: “The Oxygen Rich medical team has accumulated over 20 years of clinical research experience in pulmonary embolism, placing it in the first tier domestically in this field. The physician team comprises top-tier experts in the diagnosis and treatment of pulmonary embolism in China, possessing profound wisdom and extensive experience in supervising and guiding AI learning for pulmonary embolism. Furthermore, leveraging more than two decades of large-scale, high-quality clinical imaging data from Beijing Chaoyang Hospital, and combining the robust technical resources and rich experience in algorithm product development of the Southeast University AI team, we have developed an internationally leading intelligent diagnosis and treatment platform for pulmonary vascular diseases. This platform addresses the industry’s critical pain points of high misdiagnosis and missed diagnosis rates for pulmonary embolism.”
About Nanjing Juyi Technology
Nanjing Juyi Technology is an investment firm dedicated to discovering and investing in early-stage innovative enterprises. Its investment portfolio spans multiple sectors, including healthcare, hard technology, and clean energy. The firm provides startups with the necessary support and resources to help them stand out in a highly competitive market and fully realize their potential. Through investment and mentorship, Nanjing Juyi Technology drives technological innovation and social progress.
About the Riemann Hypothesis
Riemann-Hypothesis, founded in 2018 by Dr. Li Chaoxing upon his return from the United States, is an integrated platform dedicated to “institutionalized” industrial innovation in the early-stage life sciences sector. Adhering to its original mission of collaborating with scientist-entrepreneurs who possess global vision, profound insights, and ambitious aspirations, Riemann-Hypothesis is committed to providing early-stage investment and “full-service” operational incubation for original and pioneering biomedical projects worldwide. It has fully established its proprietary “institutionalized” incubation system, thereby breaking through the limitations of traditional technology transfer, venture capital investment, and boutique investment banking.